ArticleAnnals of the American Thoracic Society2021
Tissue Plasminogen Activator in Critically Ill Adults with COVID-19.
Article in Annals of the American Thoracic Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04343898 (Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Insight to Neglected Biomarkers in COVID-19: A Comprehensive Narrative Review".Biomarker insights · 2026Review
- Fibrinolytic system and COVID-19: From an innovative view of epithelial ion transport.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Review
- Effect of therapeutic anticoagulation on gas exchange in mechanically ventilated COVID-19 patients: A secondary analysis of the COVID-HEP trial.Thrombosis research · 2023Article
- Systemic reduced-dose alteplase for diffuse pulmonary thrombi in a COVID-19 patient.Clinical case reports · 2023Article
- The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1.Journal of thrombosis and haemostasis : JTH · 2022Article
- Fibrinolytic therapy for COVID-19: a review of case series.Acta pharmacologica Sinica · 2022Review
- Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS.Journal of intensive care · 2022Review
- MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID-19 severe respiratory failure (MUST COVID): A retrospective cohort study.Research and practice in thrombosis and haemostasis · 2022Article
- Pathophysiological mechanisms of thrombosis in acute and long COVID-19.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.